Tango Therapeutics, Inc. (NASDAQ:TNGX – Get Free Report) Director John Ketchum sold 3,333 shares of Tango Therapeutics stock in a transaction dated Tuesday, November 17th. The shares were sold at an average price of $24.08, for a total transaction of $80,258.64. Following the transaction, the director directly owned 21,604 shares of the company’s stock, valued at $520,224.32. This represents a 13.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Tango Therapeutics Trading Down 4.3%
NASDAQ:TNGX opened at $21.73 on Friday. Tango Therapeutics, Inc. has a 1 year low of $8.30 and a 1 year high of $34.39. The firm has a 50 day moving average of $23.45 and a 200-day moving average of $23.06.
Tango Therapeutics (NASDAQ:TNGX – Get Free Report) last announced its earnings results on Monday, November 9th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.04). On average, equities research analysts predict that Tango Therapeutics, Inc. will post -1.51 earnings per share for the current year.
Wall Street Analyst Weigh In
Several analysts have commented on TNGX shares. Jefferies Financial Group reiterated a “buy” rating and set a $65.00 target price on shares of Tango Therapeutics in a research report on Tuesday, November 10th. HC Wainwright dropped their price objective on Tango Therapeutics from $68.00 to $67.00 and set a “buy” rating for the company in a report on Tuesday, November 10th. Guggenheim raised their target price on Tango Therapeutics from $32.00 to $35.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. William Blair started coverage on shares of Tango Therapeutics in a report on Friday, October 16th. They set an “outperform” rating for the company. Finally, Zacks Research lowered shares of Tango Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 27th. Thirteen analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Tango Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $48.17.
Check Out Our Latest Analysis on Tango Therapeutics
Hedge Funds Weigh In On Tango Therapeutics
Large investors have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in shares of Tango Therapeutics in the 2nd quarter valued at about $388,826,000. TRV GP IV LLC bought a new position in Tango Therapeutics during the second quarter worth about $120,181,383,000. Jupiter Topco LLC acquired a new position in Tango Therapeutics during the second quarter worth approximately $157,989,000. Seven Fleet Capital Management LP increased its position in Tango Therapeutics by 302.2% during the second quarter. Seven Fleet Capital Management LP now owns 3,228,144 shares of the company’s stock worth $95,661,000 after buying an additional 2,425,484 shares during the last quarter. Finally, Jefferies Financial Group Inc. acquired a new position in Tango Therapeutics during the second quarter worth approximately $62,849,000. Institutional investors own 78.99% of the company’s stock.
About Tango Therapeutics
Tango Therapeutics is a biotechnology company focused on discovering and developing precision medicines for cancer. Based in Cambridge, Massachusetts, the company aims to develop treatments that exploit genetic differences between cancer cells and healthy cells. Its research centers on synthetic lethality, an approach that seeks to identify vulnerabilities created when cancer cells lose or alter particular genes. Tango uses this strategy to find drug targets and develop investigational therapies for tumors with specific genetic alterations.
Further Reading
- Five stocks we like better than Tango Therapeutics
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Tango Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tango Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
